Development of focal adhesion kinase inhibitors in cancer therapy

Anti-Cancer Agents in Medicinal Chemistry

Volumn 11, Issue 7, 2011, Pages 638-642

  Ma, Wen Wee ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Cancer therapy; Drug development; FAK; Focal adhesion kinase

Indexed keywords

1,2,4,5 BENZENETETRAAMINE; 2 [5 CHLORO 2 [2 METHOXY 4 (4 MORPHOLINYL)PHENYLAMINO] PYRIMIDIN 4 YLAMINO] N METHYLBENZAMIDE; ADENOSINE TRIPHOSPHATE; CFAK C4; FOCAL ADHESION KINASE; FOCAL ADHESION KINASE INHIBITOR; PF 04554878; PF 562271; TIVANTINIB; UNCLASSIFIED DRUG;

ANOREXIA; ARTICLE; CANCER THERAPY; DEHYDRATION; DIARRHEA; DIZZINESS; FATIGUE; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERBILIRUBINEMIA; HYPOKALEMIA; MUCOSA INFLAMMATION; NAUSEA; NONHUMAN; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; RECOMMENDED DRUG DOSE; SIGNAL TRANSDUCTION; VOMITING;

EID: 80051760309     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152011796817628     Document Type: Article

References (50)

1. Parsons, J. T.; Schaller, M. D.; Hildebrand, J.; Leu, T. H.; Richardson, A.; Otey, C., Focal adhesion kinase: structure and signalling. J Cell Sci Suppl 1994, 18, 109-13.
2. Parsons, J. T.; Slack-Davis, J.; Tilghman, R.; Roberts, W. G., Focal adhesion kinase: targeting adhesion signaling pathways for therapeutic intervention. Clin Cancer Res 2008, 14 (3), 627-32.
3. Gan, H. K.; Siu, L. L., Focal Adhesion Kinase as a Therapeutic Target in Cancer. ASCO 2009 Educational Book 2009, 130-136.
4. McLean, G. W.; Carragher, N. O.; Avizienyte, E.; Evans, J.; Brunton, V. G.; Frame, M. C., The role of focal-adhesion kinase in cancer - a new therapeutic opportunity. Nat Rev Cancer 2005, 5 (7), 505-15.
5. Hao, H.; Naomoto, Y.; Bao, X.; Watanabe, N.; Sakurama, K.; Noma, K.; Motoki, T.; Tomono, Y.; Fukazawa, T.; Shirakawa, Y.; Yamatsuji, T.; Matsuoka, J.; Wang, Z. G.; Takaoka, M., Focal adhesion kinase as potential target for cancer therapy (Review). Oncol Rep 2009, 22 (5), 973-9.
6. Cance, W. G.; Golubovskaya, V. M., Focal adhesion kinase versus p53: apoptosis or survival? Sci Signal 2008, 1 (20), pe22.
7. Lim, S. T.; Chen, X. L.; Lim, Y.; Hanson, D. A.; Vo, T. T.; Howerton, K.; Larocque, N.; Fisher, S. J.; Schlaepfer, D. D.; Ilic, D., Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation. Mol Cell 2008, 29 (1), 9-22.
8. Harte, M. T.; Hildebrand, J. D.; Burnham, M. R.; Bouton, A. H.; Parsons, J. T., p130Cas, a substrate associated with v-Src and v-Crk, localizes to focal adhesions and binds to focal adhesion kinase. J Biol Chem 1996, 271 (23), 13649-55.
9. Liu, Y.; Loijens, J. C.; Martin, K. H.; Karginov, A. V.; Parsons, J. T., The association of ASAP1, an ADP ribosylation factor-GTPase activating protein, with focal adhesion kinase contributes to the process of focal adhesion assembly. Mol Biol Cell 2002, 13 (6), 2147-56.
10. Taylor, J. M.; Hildebrand, J. D.; Mack, C. P.; Cox, M. E.; Parsons, J. T., Characterization of graf, the GTPase-activating protein for rho associated with focal adhesion kinase. Phosphorylation and possible regulation by mitogen-activated protein kinase. J Biol Chem 1998, 273 (14), 8063-70.
11. Weiner, T. M.; Liu, E. T.; Craven, R. J.; Cance, W. G., Expression of focal adhesion kinase gene and invasive cancer. Lancet 1993, 342 (8878), 1024-5.
12. Lipinski, C. A.; Tran, N. L.; Bay, C.; Kloss, J.; McDonough, W. S.; Beaudry, C.; Berens, M. E.; Loftus, J. C., Differential role of proline-rich tyrosine kinase 2 and focal adhesion kinase in determining glioblastoma migration and proliferation. Mol Cancer Res 2003, 1 (5), 323-32.
13. Wu, Z. M.; Yuan, X. H.; Jiang, P. C.; Li, Z. Q.; Wu, T., Antisense oligonucleodes targeting the focal adhesion kinase inhibit proliferation, induce apoptosis and cooperate with cytotoxic drugs in human glioma cells. J Neurooncol 2006, 77 (2), 117-23.
14. Xu, L. H.; Yang, X.; Craven, R. J.; Cance, W. G., The COOHterminal domain of the focal adhesion kinase induces loss of adhesion and cell death in human tumor cells. Cell Growth Differ 1998, 9 (12), 999-1005.
15. Xu, L. H.; Yang, X.; Bradham, C. A.; Brenner, D. A.; Baldwin, A. S., Jr.; Craven, R. J.; Cance, W. G., The focal adhesion kinase suppresses transformation-associated, anchorage-independent apoptosis in human breast cancer cells. Involvement of death receptor-related signaling pathways. J Biol Chem 2000, 275 (39), 30597-604.
16. Golubovskaya, V.; Beviglia, L.; Xu, L. H.; Earp, H. S., 3rd; Craven, R.; Cance, W., Dual inhibition of focal adhesion kinase and epidermal growth factor receptor pathways cooperatively induces death receptor-mediated apoptosis in human breast cancer cells. J Biol Chem 2002, 277 (41), 38978-87.
17. Xiong, W.; Parsons, J. T., Induction of apoptosis after expression of PYK2, a tyrosine kinase structurally related to focal adhesion kinase. J Cell Biol 1997, 139 (2), 529-39.
18. Smith, C. S.; Golubovskaya, V. M.; Peck, E.; Xu, L. H.; Monia, B. P.; Yang, X.; Cance, W. G., Effect of focal adhesion kinase (FAK) downregulation with FAK antisense oligonucleotides and 5- fluorouracil on the viability of melanoma cell lines. Melanoma Res 2005, 15 (5), 357-62.
19. Halder, J.; Landen, C. N., Jr.; Lutgendorf, S. K.; Li, Y.; Jennings, N. B.; Fan, D.; Nelkin, G. M.; Schmandt, R.; Schaller, M. D.; Sood, A. K., Focal adhesion kinase silencing augments docetaxelmediated apoptosis in ovarian cancer cells. Clin Cancer Res 2005, 11 (24 Pt 1), 8829-36.
20. Halder, J.; Kamat, A. A.; Landen, C. N., Jr.; Han, L. Y.; Lutgendorf, S. K.; Lin, Y. G.; Merritt, W. M.; Jennings, N. B.; Chavez-Reyes, A.; Coleman, R. L.; Gershenson, D. M.; Schmandt, R.; Cole, S. W.; Lopez-Berestein, G.; Sood, A. K., Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res 2006, 12 (16), 4916-24.
21. Halder, J.; Lin, Y. G.; Merritt, W. M.; Spannuth, W. A.; Nick, A. M.; Honda, T.; Kamat, A. A.; Han, L. Y.; Kim, T. J.; Lu, C.; Tari, A. M.; Bornmann, W.; Fernandez, A.; Lopez-Berestein, G.; Sood, A. K., Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res 2007, 67 (22), 10976-83.
22. Lipinski, C. A.; Loftus, J. C., Targeting Pyk2 for therapeutic intervention. Expert Opin Ther Targets 14 (1), 95-108.
23. Loftus, J. C.; Yang, Z.; Tran, N. L.; Kloss, J.; Viso, C.; Berens, M. E.; Lipinski, C. A., The Pyk2 FERM domain as a target to inhibit glioma migration. Mol Cancer Ther 2009, 8 (6), 1505-14.
24. Roberts, W. G.; Ung, E.; Whalen, P.; Cooper, B.; Hulford, C.; Autry, C.; Richter, D.; Emerson, E.; Lin, J.; Kath, J.; Coleman, K.; Yao, L.; Martinez-Alsina, L.; Lorenzen, M.; Berliner, M.; Luzzio, M.; Patel, N.; Schmitt, E.; LaGreca, S.; Jani, J.; Wessel, M.; Marr, E.; Griffor, M.; Vajdos, F., Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Res 2008, 68 (6), 1935-44.
25. Golubovskaya, V. M., Focal Adhesion Kinase as a Cancer Therapy Target. Anticancer Agents Med Chem 10 (10), 735-741.
26. Liu, T. J.; LaFortune, T.; Honda, T.; Ohmori, O.; Hatakeyama, S.; Meyer, T.; Jackson, D.; de Groot, J.; Yung, W. K., Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo. Mol Cancer Ther 2007, 6 (4), 1357-67.
27. Lietha, D.; Eck, M. J., Crystal structures of the FAK kinase in complex with TAE226 and related bis-anilino pyrimidine inhibitors reveal a helical DFG conformation. PLoS One 2008, 3 (11), e3800.
28. Shi, Q.; Hjelmeland, A. B.; Keir, S. T.; Song, L.; Wickman, S.; Jackson, D.; Ohmori, O.; Bigner, D. D.; Friedman, H. S.; Rich, J. N., A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth. Mol Carcinog 2007, 46 (6), 488-96.
29. Wang, Z. G.; Fukazawa, T.; Nishikawa, T.; Watanabe, N.; Sakurama, K.; Motoki, T.; Takaoka, M.; Hatakeyama, S.; Omori, O.; Ohara, T.; Tanabe, S.; Fujiwara, Y.; Shirakawa, Y.; Yamatsuji, T.; Tanaka, N.; Naomoto, Y., TAE226, a dual inhibitor for FAK and IGF-IR, has inhibitory effects on mTOR signaling in esophageal cancer cells. Oncol Rep 2008, 20 (6), 1473-7.
30. Sakurama, K.; Noma, K.; Takaoka, M.; Tomono, Y.; Watanabe, N.; Hatakeyama, S.; Ohmori, O.; Hirota, S.; Motoki, T.; Shirakawa, Y.; Yamatsuji, T.; Haisa, M.; Matsuoka, J.; Tanaka, N.; Naomoto, Y., Inhibition of focal adhesion kinase as a potential therapeutic strategy for imatinib-resistant gastrointestinal stromal tumor. Mol Cancer Ther 2009, 8 (1), 127-34.
31. Dhani, N. C.; Burris, H.; Siu, L. L.; Cambidge, D. R.; Mileshkin, L. R.; Xu, H.; Pierce, K. J.; Fahey, N. R.; Fingert, H. J.; Shreeve, S. M., Final report of phase I clinical, pharmacokinetic (PK), pharmacodynamic (PD) study of PF-00562271 targeting focal adhesion kinase (FAK) in patients (pts) with solid tumors. J Clin Oncol 28:15s, 2010 (suppl; abstr 3028).
32. Xu, H.; Yin, D.; Pierce, K. J.; Shreeve, S. M.; Duncan, B.; Bello, A., Pharmacokinetics (PK) of PF-562271, a focal adhesion kinase (FAK) inhibitor, and its effect on CYP3A in patients with advanced nonhematologic malignancies. J Clin Oncol 28:15s, 2010 (suppl; abstr 2553).
33. Siu, L. L.; Burris, H.; Mileshkin, L. R.; Camidge, R.; Eckhardt, S.; Lamb, A.; Chen, E. X.; Jones, S. F.; Xu, H.; Fingert, H., A phase I clinical, pharmacokinetic (PK) and pharmacodynamic (PD) evaluation of PF-00562271 targeting focal adhesion kinase (FAK) in patients (pts) with advanced solid tumors. J Clin Oncol 26: 2008 (May 20 suppl; abstr 3534).
34. Jones, S. F.; Shapiro, G.; Bendell, J. C.; Chen, E. X.; Bedard, P.; Cleary, J. M.; Pandya, S.; Pierce, K. J.; Houk, B.; Hosea, N.; Zandi, K. S.; Roberts, W. G.; Shreeve, S. M.; Siu, L. L., Phase I study of PF-04554878, a second-generation focal adhesion kinase (FAK) inhibitor, in patients with advanced solid tumors. J Clin Oncol 29: 2011 (suppl; abstr 3002).
35. Nishida, N.; Yano, H.; Komai, K.; Nishida, T.; Kamura, T.; Kojiro, M., Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma. Cancer 2004, 101 (6), 1364-74.
36. Liu, X. E.; Sun, X. D.; Wu, J. M., Expression and significance of VEGF-C and FLT-4 in gastric cancer. World J Gastroenterol 2004, 10 (3), 352-5.
37. He, Y.; Karpanen, T.; Alitalo, K., Role of lymphangiogenic factors in tumor metastasis. Biochim Biophys Acta 2004, 1654 (1), 3-12.
38. Stacker, S. A.; Caesar, C.; Baldwin, M. E.; Thornton, G. E.; Williams, R. A.; Prevo, R.; Jackson, D. G.; Nishikawa, S.; Kubo, H.; Achen, M. G., VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 2001, 7 (2), 186-91.
39. Skobe, M.; Hawighorst, T.; Jackson, D. G.; Prevo, R.; Janes, L.; Velasco, P.; Riccardi, L.; Alitalo, K.; Claffey, K.; Detmar, M., Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001, 7 (2), 192-8.
40. Garces, C. A.; Kurenova, E. V.; Golubovskaya, V. M.; Cance, W. G., Vascular endothelial growth factor receptor-3 and focal adhesion kinase bind and suppress apoptosis in breast cancer cells. Cancer Res 2006, 66 (3), 1446-54.
41. Kurenova, E. V.; Hunt, D. L.; He, D.; Magis, A. T.; Ostrov, D. A.; Cance, W. G., Small molecule chloropyramine hydrochloride (C4) targets the binding site of focal adhesion kinase and vascular endothelial growth factor receptor 3 and suppresses breast cancer growth in vivo. J Med Chem 2009, 52 (15), 4716-24.
42. Goldman, E. CureFAKtor Pharmaceuticals Receives Orphan Drug Designation for Its Lead Compound CFAK-C4 for the Treatment of Pancreatic Cancer. http://www.curefaktor.com/docs/ Curefaktor_Orphan_Drug_Designation_Release_Final.17120334.pdf.
43. Xing, Z.; Chen, H. C.; Nowlen, J. K.; Taylor, S. J.; Shalloway, D.; Guan, J. L., Direct interaction of v-Src with the focal adhesion kinase mediated by the Src SH2 domain. Mol Biol Cell 1994, 5 (4), 413-21.
44. Cobb, B. S.; Schaller, M. D.; Leu, T. H.; Parsons, J. T., Stable association of pp60src and pp59fyn with the focal adhesionassociated protein tyrosine kinase, pp125FAK. Mol Cell Biol 1994, 14 (1), 147-55.
45. Schaller, M. D.; Hildebrand, J. D.; Shannon, J. D.; Fox, J. W.; Vines, R. R.; Parsons, J. T., Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2-dependent binding of pp60src. Mol Cell Biol 1994, 14 (3), 1680-8.
46. Hanks, S. K.; Polte, T. R., Signaling through focal adhesion kinase. Bioessays 1997, 19 (2), 137-45.
47. Golubovskaya, V. M.; Nyberg, C.; Zheng, M.; Kweh, F.; Magis, A.; Ostrov, D.; Cance, W. G., A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth. J Med Chem 2008, 51 (23), 7405-16.
48. Hochwald, S. N.; Nyberg, C.; Zheng, M.; Zheng, D.; Wood, C.; Massoll, N. A.; Magis, A.; Ostrov, D.; Cance, W. G.; Golubovskaya, V. M., A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer. Cell Cycle 2009, 8 (15), 2435-43.
49. Ma, W. W.; Adjei, A. A., Novel agents on the horizon for cancer therapy. CA Cancer J Clin 2009, 59 (2), 111-37.
50. Yap, T. A.; Olmos, D.; Brunetto, A. T.; Tunariu, N.; Barriuso, J.; Riisnaes, R.; Pope, L.; Clark, J.; Futreal, A.; Germuska, M.; Collins, D.; deSouza, N. M.; Leach, M. O.; Savage, R. E.; Waghorne, C.; Chai, F.; Garmey, E.; Schwartz, B.; Kaye, S. B.; de Bono, J. S., Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol 29 (10), 1271-9.